ES2109986T3 - Formulado flotante en polvo de liberacion controlada. - Google Patents

Formulado flotante en polvo de liberacion controlada.

Info

Publication number
ES2109986T3
ES2109986T3 ES92309204T ES92309204T ES2109986T3 ES 2109986 T3 ES2109986 T3 ES 2109986T3 ES 92309204 T ES92309204 T ES 92309204T ES 92309204 T ES92309204 T ES 92309204T ES 2109986 T3 ES2109986 T3 ES 2109986T3
Authority
ES
Spain
Prior art keywords
controlled release
formulate
floating
pharmaceutical
release powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92309204T
Other languages
English (en)
Inventor
Andrew Dennis
Peter Timmins
Kevin Lee
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
ER Squibb and Sons LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ER Squibb and Sons LLC filed Critical ER Squibb and Sons LLC
Application granted granted Critical
Publication of ES2109986T3 publication Critical patent/ES2109986T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Adjustment And Processing Of Grains (AREA)
  • Disintegrating Or Milling (AREA)
  • Slot Machines And Peripheral Devices (AREA)
  • Detergent Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

SE PRESENTA UNA FOMULACION DE UN POLVO FARMACEUTICO DE LIBERACION CONTROLADA SOSTENIDA QUE SE PUEDE INTRODUCIR EN CAPSULAS Y LIBERA UN PRODUCTO FARMACEUTICO DE CARACTER BASICO A UNA VELOCIDAD CONTROLADA INDEPENDIENTEMENTE DEL PH DEL ENTORNO, CUYA FORMULACION INCLUYE UN PRODUCTO FARMACEUTICO BASICO, HASTA UN 45% APROXIMADAMENTE EN PESO DE UN POLIMERO DEPENDIENTE DEL PH QUE ES UNA SAL DE ACIDO ALGINICO, TAL COMO ALGINATO SODICO, HASTA UN 35% APROXIMADAMENTE EN PESO DE UN AGENTE GELIFICACION DE HIDROCARBURO INDEPENDIENTE DE PH QUE TIENE UNA VISCOSIDAD DE HASTA 100.000 CENTIPOISES EN UN 2% DE SOLUCION A 20 (GRADOS) C Y EXCIPIENTES.
ES92309204T 1991-10-23 1992-10-08 Formulado flotante en polvo de liberacion controlada. Expired - Lifetime ES2109986T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/781,620 US5169638A (en) 1991-10-23 1991-10-23 Buoyant controlled release powder formulation

Publications (1)

Publication Number Publication Date
ES2109986T3 true ES2109986T3 (es) 1998-02-01

Family

ID=25123359

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92309204T Expired - Lifetime ES2109986T3 (es) 1991-10-23 1992-10-08 Formulado flotante en polvo de liberacion controlada.

Country Status (16)

Country Link
US (1) US5169638A (es)
EP (1) EP0539059B1 (es)
JP (1) JPH05194195A (es)
AT (1) ATE161171T1 (es)
AU (1) AU660193B2 (es)
CA (1) CA2081070C (es)
DE (1) DE69223588T2 (es)
DK (1) DK0539059T3 (es)
ES (1) ES2109986T3 (es)
FI (1) FI108332B (es)
GR (1) GR3026155T3 (es)
HU (1) HU218273B (es)
MX (1) MX9205920A (es)
NO (1) NO304578B1 (es)
NZ (1) NZ244517A (es)
ZA (1) ZA927433B (es)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US5399358A (en) * 1993-11-12 1995-03-21 Edward Mendell Co., Inc. Sustained release formulations for 24 hour release of metroprolol
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
AU701042B2 (en) * 1995-02-28 1999-01-21 Aventisub Llc Pharmaceutical composition for piperidinoalkanol compounds
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
WO1998001117A1 (en) 1996-07-08 1998-01-15 Edward Mendell Co., Inc. Sustained release matrix for high-dose insoluble drugs
US6074669A (en) * 1997-01-20 2000-06-13 Ranbaxy Laboratories Limited Controlled drug delivery system for diltiazem
US20040023948A1 (en) * 1997-03-24 2004-02-05 Green Richard David Fast-dispersing dosage form containing 5-HT1 agonists
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
EE04294B1 (et) * 1997-08-26 2004-06-15 Hoechst Marion Roussel, Inc. Farmatseutiline kompositsioon piperidinoalkanooldekongestandi kombineerimiseks
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
CN1203846C (zh) 1998-03-19 2005-06-01 布里斯托尔-迈尔斯斯奎布公司 高溶解性药物的双相控释递送系统和方法
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US6143325A (en) * 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
US6524620B2 (en) 1998-07-20 2003-02-25 Andrx Pharmaceuticals, Inc. Diltiazem controlled release formulation and method of manufacture
NZ511465A (en) 1998-11-02 2003-10-31 Alza Corp Controlled delivery of active agents
NZ517465A (en) 1999-09-02 2003-10-31 Nostrum Pharmaceuticals Inc Controlled release pellet formulation
IL143375A0 (en) * 1999-09-30 2002-04-21 Penwest Pharmaceuticals Co Sustained release matrix systems for highly soluble drugs
DE10014588A1 (de) 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
FI121528B (fi) * 2000-10-30 2010-12-31 Biohit Oyj Farmaseuttinen koostumus syöpään sairastumisen riskin vähentämiseen paikallisesti sitomalla asetaldehydi syljessä, mahalaukussa tai paksusuolessa
US20110171296A1 (en) * 2000-10-30 2011-07-14 Biohit Oyj Method and preparation for binding acetaldehyde in saliva, the stomach and the large intestine
AU2002220248A1 (en) 2000-11-06 2002-05-15 Andrx Pharmaceuticals, Inc. Once a day antihistamine and decongestant formulation
AU3649502A (en) * 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
CN1551770A (zh) * 2001-07-06 2004-12-01 ������ҩ�����޹�˾ 羟吗啡酮控释制剂
US20030060422A1 (en) 2001-08-31 2003-03-27 Balaji Venkataraman Tannate compositions and methods of treatment
WO2003037301A2 (en) * 2001-10-29 2003-05-08 King Pharmaceuticals Research And Development, Inc Oral dosage forms for improving the bioavailability of therapeutic agents
US20030152621A1 (en) * 2001-11-21 2003-08-14 Egberink J. G. J. Pharmaceutical formulation of gepirone for oral administration
EP1509208A1 (en) * 2002-02-04 2005-03-02 Ranbaxy Laboratories Limited Hydrodynamically balancing oral drug delivery system with biphasic release
US7022342B2 (en) 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
EP1499295A4 (en) * 2002-04-05 2006-04-05 Penwest Pharmaceuticals Co EXTENDED RELEASE METOPROLOL FORMULATIONS
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20040086566A1 (en) * 2002-11-04 2004-05-06 Alpharma, Inc. Waxy matrix dosage forms
US8092831B2 (en) * 2002-11-08 2012-01-10 Andrx Pharmaceuticals, Llc Antihistamine and decongestant system
US7485322B2 (en) * 2002-12-24 2009-02-03 Lek Pharmaceuticals D.D. Modified release pharmaceutical composition
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
CA2512786A1 (en) * 2003-01-14 2004-08-05 Alza Corporation Methods and dosage forms with modified viscosity layers
WO2004071497A1 (en) * 2003-02-11 2004-08-26 Alza Corporation Methods and dosage forms with modified layer geometry
US7781424B2 (en) 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
EP1575565B1 (en) 2003-08-08 2010-01-06 Biovail Laboratories International Srl Modified-release tablet of bupropion hydrochloride
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
JP2007518804A (ja) 2004-01-20 2007-07-12 アラーガン、インコーポレイテッド トリアムシノロンアセトニドおよびヒアルロン酸を好ましく含有する眼局所治療用組成物
MXPA06009054A (es) * 2004-02-11 2007-04-16 Athpharma Ltd Composiciones cronoterapeuticas y metodos de su uso.
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US8455656B2 (en) 2004-04-30 2013-06-04 Allergan, Inc. Kinase inhibitors
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8591885B2 (en) 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20050244469A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US8119154B2 (en) 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244463A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
WO2005107708A1 (en) 2004-04-30 2005-11-17 Allergan, Inc. Biodegradable intravitreal tyrosine kinase inhibitors implants
US8425929B2 (en) 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20060105044A1 (en) 2004-05-20 2006-05-18 Singh Bramah N Sustained release formulations of sotalol
US8691272B2 (en) * 2005-12-30 2014-04-08 Intelgenx Corp. Multilayer tablet
US20070178155A1 (en) * 2006-01-31 2007-08-02 Jiang David Yihai Preparation for gastric buoyant sustained drug release dosage form
US8802128B2 (en) * 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
TW200827336A (en) 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
EP2133071A1 (en) * 2008-06-09 2009-12-16 Université de la Méditerranée Process for making gastroretentive dosage forms
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
CN102724951A (zh) 2009-11-09 2012-10-10 阿勒根公司 用于刺激毛发生长的组合物和方法
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
WO2013019891A1 (en) * 2011-08-01 2013-02-07 St. Hill Pharmaceutical Corporation Non-digestible capsules for the delivery of fluid absorbing materials
KR20200060734A (ko) * 2012-03-23 2020-06-01 파마73, 에스.에이. 피키아 파스토리스 바이오매스로부터 제조된 천연 바이오복합재 분말, 제조방법, 및 부형제로서의 이의 용도
EP2956096A1 (en) 2013-02-15 2015-12-23 Allergan, Inc. Sustained drug delivery implant
AU2014270109B2 (en) 2013-05-24 2017-05-25 Rhodes Technologies Opioid ketal compounds and uses thereof
SG11201609605RA (en) 2014-05-21 2016-12-29 Pharma73 S A Chitin-glucan complex, its preparation, and uses
CN111836813A (zh) 2018-02-23 2020-10-27 罗德科技公司 新型阿片样化合物及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140755A (en) * 1976-02-13 1979-02-20 Hoffmann-La Roche Inc. Sustained release tablet formulations
US4167558A (en) * 1976-02-13 1979-09-11 Hoffmann-La Roche Inc. Novel sustained release tablet formulations
US4101650A (en) * 1977-04-06 1978-07-18 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Pepstatin floating minicapsules
CH652025A5 (de) * 1981-09-14 1985-10-31 Hoffmann La Roche Pharmazeutisches praeparat.
DE3586281T2 (de) * 1984-04-19 1992-12-10 Rhone Poulenc Rorer Int Antisaeurezusammensetzung.
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
PL149493B1 (en) * 1985-04-12 1990-02-28 Method of obtaining a tablet capable to buoy over surface of gastric juice
US4814178A (en) * 1987-07-01 1989-03-21 Sanford Bolton Floating sustained release therapeutic compositions
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
AU627775B2 (en) * 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions

Also Published As

Publication number Publication date
CA2081070A1 (en) 1993-04-24
NO924104L (no) 1993-04-26
CA2081070C (en) 2002-12-24
AU660193B2 (en) 1995-06-15
ATE161171T1 (de) 1998-01-15
FI924831A (fi) 1993-04-24
NZ244517A (en) 1994-10-26
US5169638A (en) 1992-12-08
DK0539059T3 (da) 1998-01-26
HU9203342D0 (en) 1992-12-28
AU2716792A (en) 1993-04-29
DE69223588T2 (de) 1998-06-25
FI108332B (fi) 2002-01-15
GR3026155T3 (en) 1998-05-29
MX9205920A (es) 1993-06-01
HUT63325A (en) 1993-08-30
FI924831A0 (fi) 1992-10-23
ZA927433B (en) 1993-04-07
NO304578B1 (no) 1999-01-18
HU218273B (en) 2000-07-28
NO924104D0 (no) 1992-10-22
EP0539059B1 (en) 1997-12-17
DE69223588D1 (de) 1998-01-29
EP0539059A1 (en) 1993-04-28
JPH05194195A (ja) 1993-08-03

Similar Documents

Publication Publication Date Title
ES2109986T3 (es) Formulado flotante en polvo de liberacion controlada.
DE3750145D1 (de) Zusammensetzung mit kontrollierter Freisetzung von Dihydrocodein.
DK74187D0 (da) Praeparat til langsom frigivelse samt fremgangsmaade til fremstilling deraf
GB1533283A (en) Mixtures for anchoring bone implants
DK187387D0 (da) Gelatinekapsler og fremgangsmaade til fremstilling heraf
ATE67933T1 (de) Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung.
ES2173096T3 (es) Composicion farmaceutica peletizada.
ES510245A0 (es) "un metodo para obtener una preparacion de insulina".
JPS6479109A (en) Floating continuous release therapy composition
FI861553A0 (fi) Paisuneita makromolekyylejä sisältävän vesiseosjärjestelmän käyttö sammutusvetenä
ES2053528T5 (es) Composicion farmaceutica que comprende un medicamento y un polimero hinchable en agua.
FR2649710B1 (es)
US5776987A (en) Pharmaceutical suspension formulation
EP0416722A3 (en) Pharmaceutical compositions having differential drug release rate
KR950023409A (ko) 숙취 치료용 조성물 및 이를 사용하여 숙취를 치료하는 방법
JPS5534058A (en) Immobilization of bioactive substance to powdery carrier

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 539059

Country of ref document: ES